Ligand Pharmaceuticals Inc (LGND) insider trading.
In Q3 2026, insiders at Ligand Pharmaceuticals Inc reported 38 non-derivative transactions on 9 Forms 3, 4 and 5: 0 open-market purchases and 26 sales worth $16.1M.
- Transactions
- 38
- Purchases (P)
- 0
- Sales (S)
- 26
- Net shares, P minus S
- -54,979
- Insiders
- 5
- Last filed
- 2026-09-24
Insiders
| Insider | Relationship | Transactions | Buys | Sales |
|---|---|---|---|---|
| Reardon Andrew | Officer · CLO & Secretary | 26 | 0 | 23 |
| Espinoza Octavio | Officer · Chief Financial Officer | 7 | 0 | 1 |
| Zimmermann Martine | Director | 2 | 0 | 1 |
| Haas Jason | Director | 2 | 0 | 1 |
| Davis Todd C | Director, Officer · Chief Executive Officer | 1 | 0 | 0 |
Transactions
| Date | Insider | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-22 | Zimmermann Martine | F (D) | 115 | $298.5 | 3,782 | Form 4 |
| 2026-09-10 | Zimmermann Martine | S (D) | 1,200 | $285 | 3,897 | Form 4 |
| 2026-09-03 | Reardon Andrew | S (D) | 385 | $287.53 | 36,914 | Form 4 |
| 2026-09-03 | Reardon Andrew | S (D) | 1,800 | $285.17 | 39,414 | Form 4 |
| 2026-09-03 | Reardon Andrew | S (D) | 2,115 | $286.36 | 37,299 | Form 4 |
| 2026-09-03 | Reardon Andrew | S (D) | 300 | $283.99 | 41,214 | Form 4 |
| 2026-09-03 | Reardon Andrew | S (D) | 400 | $288.98 | 36,514 | Form 4 |
| 2026-08-12 | Haas Jason | M (A) | 6,138 | $51.56 | 11,119 | Form 4 |
| 2026-08-12 | Haas Jason | S (D) | 7,138 | $292.81 | 3,981 | Form 4 |
| 2026-08-12 | Espinoza Octavio | M (A) | 16,179 | $52.84 | 43,875 | Form 4 |
| 2026-08-12 | Espinoza Octavio | M (A) | 3,348 | $68.74 | 59,337 | Form 4 |
| 2026-08-12 | Espinoza Octavio | M (A) | 7,171 | $57.22 | 55,989 | Form 4 |
| 2026-08-12 | Espinoza Octavio | S (D) | 31,641 | $292.07 | 27,696 | Form 4 |
| 2026-08-12 | Espinoza Octavio | M (A) | 2,074 | $70.04 | 45,949 | Form 4 |
| 2026-08-12 | Espinoza Octavio | M (A) | 2,869 | $55.75 | 48,818 | Form 4 |
| 2026-08-03 | Reardon Andrew | S (D) | 200 | $290.6 | 42,914 | Form 4 |
| 2026-08-03 | Reardon Andrew | S (D) | 991 | $291.71 | 41,923 | Form 4 |
| 2026-08-03 | Reardon Andrew | S (D) | 409 | $292.82 | 41,514 | Form 4 |
| 2026-08-03 | Reardon Andrew | M (A) | 5,000 | $52.27 | 46,514 | Form 4 |
| 2026-08-03 | Reardon Andrew | S (D) | 105 | $284.14 | 46,409 | Form 4 |
| 2026-08-03 | Reardon Andrew | S (D) | 33 | $284.55 | 46,376 | Form 4 |
| 2026-08-03 | Reardon Andrew | S (D) | 157 | $285.74 | 46,219 | Form 4 |
| 2026-08-03 | Reardon Andrew | S (D) | 1,032 | $286.8 | 45,187 | Form 4 |
| 2026-08-03 | Reardon Andrew | S (D) | 1,214 | $287.77 | 43,973 | Form 4 |
| 2026-08-03 | Reardon Andrew | S (D) | 356 | $288.75 | 43,617 | Form 4 |
| 2026-08-03 | Reardon Andrew | S (D) | 503 | $289.8 | 43,114 | Form 4 |
| 2026-07-01 | Reardon Andrew | S (D) | 600 | $317.15 | 41,514 | Form 4 |
| 2026-07-01 | Reardon Andrew | S (D) | 900 | $315.78 | 42,114 | Form 4 |
| 2026-07-01 | Reardon Andrew | S (D) | 100 | $314.58 | 43,014 | Form 4 |
| 2026-07-01 | Reardon Andrew | S (D) | 700 | $313.46 | 43,114 | Form 4 |
| 2026-07-01 | Reardon Andrew | S (D) | 1,081 | $312.28 | 43,814 | Form 4 |
| 2026-07-01 | Reardon Andrew | S (D) | 1,119 | $311.72 | 44,895 | Form 4 |
| 2026-07-01 | Reardon Andrew | S (D) | 104 | $310.2 | 46,014 | Form 4 |
| 2026-07-01 | Reardon Andrew | S (D) | 396 | $308.99 | 46,118 | Form 4 |
| 2026-07-01 | Reardon Andrew | M (A) | 5,000 | $52.27 | 46,514 | Form 4 |
| 2026-06-30 | Davis Todd C | J (A) | 132 | $160.71 | 199,513 | Form 4 |
| 2026-06-30 | Espinoza Octavio | J (A) | 17 | $160.71 | 27,696 | Form 4 |
| 2026-06-30 | Reardon Andrew | J (A) | 132 | $160.71 | 41,514 | Form 4 |
Transaction codes in this quarter
Get LGND insider transactions through the API
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=886163&limit=100" \
-H "Authorization: Bearer $SEC_API_KEY"Insider trading API guide · LGND company page · Ligand Pharmaceuticals Inc on SEC.gov
Questions
Are insiders buying or selling Ligand Pharmaceuticals Inc (LGND)?
In Q3 2026, insiders at Ligand Pharmaceuticals Inc reported 38 non-derivative transactions on 9 Forms 3, 4 and 5: 0 open-market purchases and 26 sales worth $16.1M. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.
Where do these Ligand Pharmaceuticals Inc insider trades come from?
From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.
Plain-text version for agents and LLMs: /insider-trading/lgnd.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.